Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 1/20 | 0.40 |
| ▸ | BCHE | P06276 | 1/20 | 0.32 |
| ▸ | ACHE | P22303 | 1/20 | 0.32 |
| ▸ | EGFR | P00533 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31712908 | 0.78 | EGFR (0.33) | EGFRKDM4ECYP1A2CYP3A4 | |
| SCHEMBL5865477 | 0.76 | MAPT (0.52) | NOTUMBCHEACHEKDM4ECYP3A4 | |
| SCHEMBL13154670 | 0.73 | CHRNB2 (0.33) | EGFRKDM4ECYP1A2CYP3A4 | |
| SCHEMBL13154683 | 0.73 | NOTUM (0.40) | NOTUMEGFR | |
| SCHEMBL13154633 | 0.72 | NOTUM (0.42) | NOTUMBCHEACHE | |
| SCHEMBL13154668 | 0.69 | CDC7 (0.44) | NOTUMACHEKDM4ECYP1A2CYP3A4 | |
| SCHEMBL13154665 | 0.69 | NOTUM (0.42) | NOTUMBCHEACHE | |
| SCHEMBL30790389 | 0.69 | EGFR (0.38) | EGFR | |
| SCHEMBL13154666 | 0.68 | NOTUM (0.44) | NOTUMBCHEACHEKDM4ECYP1A2 | |
| SCHEMBL31712925 | 0.68 | SRC (0.33) | EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11980086-B2 | Use of transition metal carbene complexes in organic light-emitting diodes (OLEDs) | UDC IRELAND LIMITED (IE) | 2024-05-07 | — | — | US | disclosed |
| US-20240074302-A1 | USE OF TRANSITION METAL CARBENE COMPLEXES IN ORGANIC LIGHT-EMITTING DIODES (OLEDS) | UDC IRELAND LTD (IE) | 2024-02-29 | — | — | US | disclosed |
| US-20140309428-A1 | USE OF TRANSITION METAL CARBENE COMPLEXES IN ORGANIC LIGHT-EMITTING DIODES (OLEDS) | BASF SE (DE) | 2014-10-16 | — | — | US | disclosed |
| US-7803948-B2 | Method for the isomerisation of transition metal complexes containing cyclometallated, carbene ligands | BASF AKTIENGESELLSCHAFT (DE) | 2010-09-28 | — | — | US | disclosed |
| US-20080200686-A1 | Method for the Isomerisation of Transition Metal Complexes Containing Cyclometallated, Carbene Ligands | BASF AKTIENGESELLSCHAFT (DE) | 2008-08-21 | — | — | US | disclosed |
| US-20080018221-A1 | Use Of Transition Metal Carbene Complexes In Organic Light-Emitting Diodes (Oleds) | BASF AKTIENGESELLSCHAFT (DE) | 2008-01-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080200686-A1 | Method for the Isomerisation of Transition Metal Complexes Containing Cyclometallated, Carbene Ligands | SCO2, CYC1, CHRM1 | NOTUM 4627/4885BCHE 4362/4885ACHE 4528/4885 |
| US-11980086-B2 | Use of transition metal carbene complexes in organic light-emitting diodes (OLEDs) | OCIAD2, OCIAD1, ICOSLG | NOTUM 1860/4885BCHE 3829/4885ACHE 1779/4885 |
| US-20080018221-A1 | Use Of Transition Metal Carbene Complexes In Organic Light-Emitting Diodes (Oleds) | OCIAD2, OCIAD1, ICOSLG | NOTUM 1860/4885BCHE 3829/4885ACHE 1779/4885 |
| US-20240074302-A1 | USE OF TRANSITION METAL CARBENE COMPLEXES IN ORGANIC LIGHT-EMITTING DIODES (OLEDS) | OCIAD2, OCIAD1, ICOSLG | NOTUM 1860/4885BCHE 3829/4885ACHE 1779/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.